The Current Scenario for Interstitial Cystitis(IC)

Interstitial cystitis (IC), also known as painful bladder syndrome, is a chronic disease that results in recurring discomfort or pain in the bladder and the surrounding pelvic region. This is considered as multiple bladder conditions as it can lead to many other problems. Interstitial cystitis can be of two types: Non-Ulcerative (90% of IC cases) and Ulcerative (5%-10% of IC cases), where the exact cause is unknown. However, researchers believe that many factors are at play which may contribute to the development of the condition like Bladder trauma, Bladder over-distention, pelvic floor muscle dysfunction, and bacterial infection (cystitis), etc. Damage to the bladder wall allows particles in the urine, such as potassium, to leak into the bladder lining.

The diagnosis of interstitial cystitis can be challenging as the patient poses a variety of symptoms that may be difficult to diagnose and may also lead to misdiagnosis, underdiagnosis and delayed diagnosis. United States has the highest incident probable IC Cases. 90% of IC cases occur in women. Though only 10% of IC cases occur in men, it is believed that is underestimated due to misdiagnosis.

The Interstitial Cystitis market is mainly driven by Elmiron, which is the only approved oral drug by FDA specifically for IC. Another option includes bladder instillations like Cystistat, Hyacyst, Uracyst, etc., which are not approved by FDA. NSAIDs, Anti-depressants, anti-histamines, etc are also used for controlling symptoms of IC. The overall market of IC in 7 major markets for Elmiron and bladder instillations was found to be around USD 261.3 millions, of which major share is of U.S.

With drugs in the pipeline for IC, the market is expected to grow at a steady rate. There is no cure for interstitial cystitis (IC). However, many treatment options are available to help relieve the symptoms of bladder pain, urgency, and frequency. The combination of various treatments is the best approach to treating interstitial cystitis.

Insight by:
Anuj Thakur
Analyst

DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutic indications. DelveInsight has a database of 3000+ high-quality analytical reports.

Statistical Insight on Some Common Cancers

Cancer is the leading cause of morbidity and mortality worldwide and one in every seven deaths is due to cancer. It has the worst incidence and mortality statistics. According to the International Agency for Research on Cancer (IARC), an estimated 14.1 million new cases of cancer occur with mortality of 8.2 million worldwide. There are more than 100 types of cancer. Here, in this article, statistical insight is shed on few of the major cancers viz.  lung cancer, breast cancer, colorectal cancer and prostate cancer.

  • Lung cancer is one of the wide spread cancer, World Health Organization (WHO) has reported that there were an estimated 1.8 million new cases for lung cancer in 2012 and 1.59 million estimated deaths globally. As reported by the American Cancer Society, the estimated new cases for lung cancer in 2017 would be around 222,500 and the estimated mortality would be around 155,870 in US alone. There are approximately 52 drugs approved for the treatment of Non-Small Cell Lung Cancer, showing an increased effort towards treating lung cancer.
  • Breast Cancer is also one of the most common cancers, and WHO has reported that there were estimated 1.67 million new cases in 2012 and 522,000 million estimated deaths globally. As reported by the American Cancer Society, the estimated new cases for invasive breast cancer and in situ breast cancer in 2017 would be around 252,710 and 63,410 respectively and the estimated mortality would be around 40,610 in US alone. There are approximately 63 drugs approved for the treatment of breast cancer, and a vast pipeline aiming to decrease the mortality associated with this type.
  • The statistics of WHO in terms of colorectal cancer show that globally there were around 1.36 million new cases for colorectal cancer in 2012 and 694,000 estimated deaths. As reported by the American Cancer Society, the estimated new cases in 2014 were around 136,830 and the estimated mortality was around 50,310 in US alone.
  • Prostate Cancer has also become a concern in terms of mortality and morbidity, with WHO reporting that globally there would be estimated 1.09 million new cases for prostate cancer in 2012 and 307,000 estimated deaths. The American Cancer Society also estimates new cases for colorectal cancer in 2017 to be around 161,360 and the estimated mortality to be around 26,730 in US alone. There are approximately 28 drugs approved for the treatment of prostate cancer, showing immense R&D interest.

Insight by:
Yuktie
Associate Analyst

DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business and facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutical indications. Delveinsight has a database of 3000+ high-quality analytical reports

US drug approvals plummet in 2016

US drug approvals are on track to drop by more than half in 2016 compared to 2015. The agency had approved 19 new drugs this year as of 9 December, putting it on track for its lowest yearly tally since 2007. The decline is made more dramatic by 2015’s bumper crop of approvals. The FDA approved 45 new drugs last year — the highest total in nearly 20 years. The data come as the agency waits to find out who will be its next commissioner under US president-elect Donald Trump, as he has indicated that he wants to speed up drug approvals and cut through “the red tape at the FDA”. And on 13 December, President Barack Obama signed into law the 21st Century Cures Act, which includes measures intended to streamline drug approvals.

To read more, click here.